<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593329</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1519 - TIRADENTES 500/50</org_study_id>
    <nct_id>NCT04593329</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain</brief_title>
  <official_title>National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Tiradentes association in&#xD;
      adolescents and adults with acute pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Sum of Pain Intensity Difference Over 6 Hours (SPID0-6)</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Sum of pain intensity differences after 6 hours (SPID0-6), calculated as the weighted sum of pain intensity scale over 6 hours after the dose. Scoring is derived from the 4-point scale, which 0= no pain, 1= mild pain, 2= moderate pain and 4= severe pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>TIRADENTES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:&#xD;
1 tablet Tiradentes association, oral;&#xD;
1 capsule tramadol placebo, oral;&#xD;
1 tablet dipyrone placebo, oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DIPYRONE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:&#xD;
1 tablet dipyrone, oral;&#xD;
1 tablet Tiradentes association placebo, oral;&#xD;
1 capsule tramadol placebo, oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAMADOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:&#xD;
1 capsule tramadol, oral;&#xD;
1 tablet dipyrone placebo, oral;&#xD;
1 tablet Tiradentes association placebo, oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIRADENTES ASSOCIATION</intervention_name>
    <description>Tiradentes association tablet</description>
    <arm_group_label>TIRADENTES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIPYRONE</intervention_name>
    <description>Dipyrone 500 mg</description>
    <arm_group_label>DIPYRONE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRAMADOL</intervention_name>
    <description>Tramadol 50 mg</description>
    <arm_group_label>TRAMADOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TIRADENTES ASSOCIATION PLACEBO</intervention_name>
    <description>Tiradentes association placebo tablet</description>
    <arm_group_label>DIPYRONE</arm_group_label>
    <arm_group_label>TRAMADOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DIPYRONE PLACEBO</intervention_name>
    <description>Dipyrone placebo tablet</description>
    <arm_group_label>TIRADENTES</arm_group_label>
    <arm_group_label>TRAMADOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TRAMADOL PLACEBO</intervention_name>
    <description>Tramadol placebo capsule</description>
    <arm_group_label>DIPYRONE</arm_group_label>
    <arm_group_label>TIRADENTES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Participants of both sexes, aged 15 years or more;&#xD;
&#xD;
          -  Participants who require extraction of impacted mandibular third molar;&#xD;
&#xD;
          -  Third molar with bone impactions observed in panoramic radiography, with&#xD;
             classification of Winter (1926) mesioangular or vertical, and classification according&#xD;
             to Pell &amp; Gregory (1933) class II position B or class III position A or B;&#xD;
&#xD;
          -  Participants with acute pain of moderate or severe intensity after completion of&#xD;
             surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  History of alcohol and/or substance abuse within 2 years;&#xD;
&#xD;
          -  Participants whose surgery for molar extraction lasted more than 50 minutes;&#xD;
&#xD;
          -  Participants with known gastroduodenal ulcers or diagnosis of persistent gastritis;&#xD;
&#xD;
          -  Participants who used sedatives or hypnotic agents before surgery;&#xD;
&#xD;
          -  Anesthesia technical failure or need for more than three anesthetic tubes;&#xD;
&#xD;
          -  Participants with temporomandibular joint dysfunction or limited mouth opening;&#xD;
&#xD;
          -  Surgical accident that, in the investigator's opinion, may interfere with the&#xD;
             procedures or evaluations of the trial;&#xD;
&#xD;
          -  Postoperative complications such as, but not restricted to: neuropraxia and&#xD;
             paresthesia;&#xD;
&#xD;
          -  Participants who used any medication that acts on the pain mechanism in the 3 days&#xD;
             prior to the start of the trial;&#xD;
&#xD;
          -  Participants under chronic opioid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

